Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Beam Therapeutics (BEAM)
NASDAQ:BEAM
Holding BEAM?
Track your performance easily
BEAM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$20.84 - $49.50
Previous CloseN/A
Volume491.48K
Average Volume (3M)1.24M
Market Cap
$1.93B
Enterprise Value$1.26B
Total Cash (Recent Filing)$1.90M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.53
Next Earnings
Mar 04, 2025EPS Estimate
-1.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.76
Shares Outstanding82,805,626
10 Day Avg. Volume1,428,550
30 Day Avg. Volume1,240,104
Standard Deviation0.26
R-Squared0.15
Alpha0.00448
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.54
Price to Cash Flow (P/CF)-5.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.65
Enterprise Value/Revenue3.59
Enterprise Value/Gross Profit3.32
Enterprise Value/Ebitda-8.76
Forecast
1Y Price Target
$50.00Price Target Upside113.68% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
Beam Therapeutics News
PremiumCompany Announcements
Beam Therapeutics Advances Base Editing Portfolio
PremiumCompany Announcements
Beam Therapeutics Advances BEAM-101 Therapy for Sickle CellBulls Say, Bears Say
Bulls Say
Financial StabilityBEAM's strong cash position of $850.7MM is sufficient to fund operations and capital expenditures into 2027, supporting the company's financial stability.
Regulatory ApprovalFDA and DMC have approved the enrollment of adolescent patients aged 12-17 years into the BEACON study, expanding the potential patient pool.
Research CollaborationsResearch collaborations with PFE and APLS are ongoing, with the APLS collaboration advancing preclinical studies for a base editing treatment targeting the neonatal Fc receptor.
Bears Say
Clinical DataBeam Therapeutics has not yet presented any clinical data from any of its programs, which is essential to justify its current valuation.
Market CompetitionThe company's lead indication for sickle cell disease is in a crowded market, with competitors already ahead in terms of clinical data.
Safety ConcernsA patient died of respiratory failure, highlighting the need for less toxic preconditioning treatments.
---
Ownership Overview
26.97% Insiders
16.69% Mutual Funds
0.09% Other Institutional Investors
31.74% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BEAM FAQ
What was Beam Therapeutics’s price range in the past 12 months?
Beam Therapeutics lowest stock price was $20.84 and its highest was $49.50 in the past 12 months.
What is Beam Therapeutics’s market cap?
Beam Therapeutics’s market cap is $1.93B.
When is Beam Therapeutics’s upcoming earnings report date?
Beam Therapeutics’s upcoming earnings report date is Mar 04, 2025 which is in 45 days.
How were Beam Therapeutics’s earnings last quarter?
Beam Therapeutics released its earnings results on Nov 05, 2024. The company reported -$1.17 earnings per share for the quarter, beating the consensus estimate of -$1.183 by $0.013.
Is Beam Therapeutics overvalued?
According to Wall Street analysts Beam Therapeutics’s price is currently Undervalued.
Does Beam Therapeutics pay dividends?
Beam Therapeutics does not currently pay dividends.
What is Beam Therapeutics’s EPS estimate?
Beam Therapeutics’s EPS estimate is -1.27.
How many shares outstanding does Beam Therapeutics have?
Beam Therapeutics has 82,805,626 shares outstanding.
What happened to Beam Therapeutics’s price movement after its last earnings report?
Beam Therapeutics reported an EPS of -$1.17 in its last earnings report, beating expectations of -$1.183. Following the earnings report the stock price went down -1.765%.
Which hedge fund is a major shareholder of Beam Therapeutics?
Among the largest hedge funds holding Beam Therapeutics’s share is Farallon Capital Management, L.L.C.. It holds Beam Therapeutics’s shares valued at 201M.
---
Beam Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$50.00 (113.68% Upside)
$50.00 (113.68% Upside)
Blogger Sentiment
Bullish
BEAM Sentiment 75%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 814.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.2%
Last 30 Days ▲ 1.6%
Last 30 Days ▲ 1.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-6.77%
12-Months-Change
Fundamentals
Return on Equity
-18.29%
Trailing 12-Months
Asset Growth
-9.23%
Trailing 12-Months
Company Description
Beam Therapeutics
Beam Therapeutics, Inc. develops and commercializes DNA base editing technologies for the treatment of human disease. Its licensed technology platform, which includes access to base editing technologies and associated technologies that enhance the scope of base editing. The company was founded by David R. Liu, Feng Zhang and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.
---
BEAM Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of significant advancements in Beam's clinical programs, particularly in sickle cell disease and liver genetic diseases, alongside notable challenges related to patient safety in ongoing trials. While the progress in clinical data and technology development is promising, the safety concerns related to conditioning agents are a critical issue.Read More>---
BEAM Stock 12 Month Forecast
Average Price Target
$50.00
▲(113.68% Upside)
Technical Analysis
Intellia Therapeutics
―
Editas Medicine
―
Crispr Therapeutics AG
―
Sangamo Biosciences
―
Verve Therapeutics
―
Precigen
―
Best Analysts Covering BEAM
1 Year
1 Year Success Rate
7/13 ratings generated profit
1 Year Average Return
-3.65%
reiterated a buy rating 4 days ago
Copying Yanan Zhu's trades and holding each position for 1 Year would result in 53.85% of your transactions generating a profit, with an average return of -3.65% per trade.
---